Valsartan NDMA Contamination Cancer Lawsuit: What You Need to Know

Valsartan was one of the most commonly prescribed blood pressure medications in the United States before a manufacturing contamination scandal upended millions of patients’ sense of security in 2018. The drug itself is not inherently dangerous — it belongs to a well-established class of antihypertensives. The problem was what ended up inside certain batches of it: NDMA, a chemical the International Agency for Research on Cancer classifies as a probable human carcinogen.

For patients who took contaminated valsartan — sometimes for years without knowing — the discovery raised an urgent and deeply unsettling question: Could this medication have caused my cancer?

That question is now at the center of one of the largest pharmaceutical multidistrict litigations in recent U.S. history.

This article explains what actually happened, what the science says, how the litigation is structured, and — critically — what practical steps you should take now if you or a family member may have been affected. It is written for a general U.S. audience navigating an unfamiliar legal landscape, not for pharmaceutical or legal professionals who already know the terrain.

---

What Is Valsartan and Who Takes It?

Valsartan is an angiotensin receptor blocker (ARB), a drug class that works by blocking the action of angiotensin II, a hormone that narrows blood vessels. By blocking this receptor, valsartan allows blood vessels to relax and widen, reducing blood pressure and the workload on the heart.

Physicians prescribe it for:

• Hypertension (high blood pressure)
• Heart failure, particularly to reduce hospitalization risk
• Post-myocardial infarction (heart attack recovery) to improve survival

ARBs like valsartan are considered effective, well-tolerated medications with decades of clinical use behind them. Valsartan is sold under the brand name Diovan by Novartis but is also widely available as a generic. The millions of patients taking it — mostly older adults managing chronic cardiovascular conditions — had no reason to question its safety until 2018.

Valsartan’s generic versions became especially dominant in the U.S. market after Novartis’s patent exclusivity expired. Lower-cost generics from manufacturers sourcing API overseas became the standard dispensed form in pharmacies across the country. That shift — from a single branded manufacturer to a web of generic makers relying on overseas active ingredient suppliers — is part of the infrastructure that made the contamination problem possible.

That trust was shattered not by the drug’s mechanism but by what happened during its manufacture.

---

How Did NDMA End Up in a Blood Pressure Pill?

The contamination did not result from sabotage or negligence in the traditional sense of a quality control lapse. It was the consequence of a deliberate process change that created an unintended chemical reaction.

Zhejiang Huahai Pharmaceutical Co. (ZHP), a Chinese manufacturer supplying active pharmaceutical ingredients (API) to finished-dose manufacturers worldwide, modified its synthesis process for valsartan API. Specifically, ZHP began reusing solvents — dimethylformamide (DMF) — in the production process rather than using fresh solvent each time.

This change, intended to reduce costs and waste, triggered a chemical reaction. The reused solvent, combined with other reagents in the synthesis, produced N-nitrosodimethylamine (NDMA) as a byproduct. NDMA is not supposed to be in a pharmaceutical product at all. The FDA’s established acceptable daily intake limit for NDMA is 96 nanograms per day — a threshold established based on cancer risk modeling.

Testing later found NDMA levels in some recalled valsartan API batches far in excess of that threshold.

The contamination had been occurring for years before it was detected. It was only discovered in 2018 when a European pharmaceutical company independently tested valsartan API using more sensitive analytical methods than were standard practice at the time.

When that European company flagged the finding, it triggered a regulatory chain reaction. Health authorities in Europe and the FDA communicated; ZHP and finished-dose manufacturers were put on notice. The cascade of recalls that followed was, in part, a reaction to the inadequacy of prior testing rather than to a new contamination event.

This is a key detail for litigation: ZHP’s process change happened years before the 2018 recall. Patients may have been exposed to elevated NDMA levels throughout that extended period — potentially starting as early as 2012, depending on when the process change was implemented. The duration of prior exposure is central to the causation and damages analysis in individual cases.

---

The 2018 FDA Recall: Scope and What Happened

The FDA began issuing recall notices for valsartan products in July 2018. The initial recalls targeted products using API from ZHP. But as regulators expanded testing — both in the U.S. and internationally through coordinated action with the European Medicines Agency (EMA) — additional manufacturers and lots were added.

The recalls were not limited to ZHP’s API alone. The FDA also identified NDMA and related nitrosamines (including NDEA, N-nitrosodiethylamine) in products from other manufacturers as the scope of industry-wide testing broadened.

What the recall covered:

• Finished-dose valsartan tablets from multiple manufacturers
• Combination products (e.g., valsartan/hydrochlorothiazide)
• Products distributed under various brand and generic labels

What patients were told: The FDA advised patients not to abruptly stop taking their valsartan without consulting a physician — discontinuing blood pressure medication suddenly carries its own cardiovascular risks, including rebound hypertension. Instead, patients were told to contact their pharmacy and physician to transition to an unaffected alternative.

This created a logistical challenge: patients needed to know which product they were taking, whether it was recalled, and whether an alternative was available — all while managing an active chronic condition that couldn’t simply be paused. For many patients who had no idea their medication had been reformulated from an overseas API source, the recall came entirely out of the blue.

For many, that guidance came too late to address what may have been years of prior exposure.

Recall Wave	Scope
July 2018	Initial ZHP-sourced valsartan API products recalled
August–October 2018	Additional manufacturers and combination products added
Late 2018–2019	Losartan and irbesartan products with related contamination recalled
April 2020	Ranitidine (Zantac) withdrawn entirely (different mechanism but same NDMA concern)

To check whether a specific product was recalled, the FDA maintains a searchable recall database at fda.gov. Lot numbers, manufacturers, and NDC codes for recalled products are listed there.

---

Why Is NDMA Dangerous? Understanding the Cancer Classification

NDMA (N-Nitrosodimethylamine) is a member of the nitrosamine family of chemicals. It occurs naturally in very small amounts in some foods and water supplies, but at high levels, it has been consistently shown to cause cancer in animal studies across multiple species and exposure routes.

The International Agency for Research on Cancer (IARC) classifies NDMA as Group 2A: Probably carcinogenic to humans. This classification means:

IARC Classification	What It Means
Group 1	Carcinogenic to humans (definitive evidence)
Group 2A	Probably carcinogenic to humans (strong animal data, limited human data)
Group 2B	Possibly carcinogenic to humans (suggestive but less consistent evidence)
Group 3	Not classifiable as to carcinogenicity

Group 2A is not a low-concern designation. The U.S. Environmental Protection Agency (EPA) also lists NDMA as a probable human carcinogen. The FDA’s 96 nanogram per day acceptable daily intake limit for NDMA in pharmaceuticals is designed to keep added lifetime cancer risk below a specific threshold — not to suggest that any NDMA exposure is automatically safe.

In pharmaceutical exposure, the concern is chronic, daily ingestion — not a one-time exposure. A patient taking a daily valsartan tablet for years, if that tablet contained elevated NDMA, would have accumulated substantially more exposure than the acceptable daily intake standard contemplates.

Consider the math in rough terms: if NDMA levels in some batches were measured in hundreds of nanograms per tablet — above the 96 nanogram daily intake threshold — a patient taking that tablet once per day for three years would have consumed NDMA on thousands of occasions at elevated levels. Whether that accumulation reaches a medically significant threshold is a question for expert toxicologists and epidemiologists, not a conclusion to draw from headlines alone. But it underscores why this is treated as a serious cancer risk question rather than a theoretical one.

Animal studies show NDMA causes tumors in the liver, kidneys, and other organs depending on dosage and species. The relevance to human exposure is the basis of the legal claims, even if establishing individual causation requires expert medical testimony in each case.

It is also worth noting what IARC Group 2A does not mean. It does not mean NDMA has been proven in randomized human trials to cause cancer — such trials would be unethical to conduct. It means the totality of animal evidence and available human epidemiological data is strong enough that regulators and researchers treat it as a probable cancer-causing substance. That evidentiary standard supports both regulatory action and civil litigation even without the kind of controlled human studies that would remove all scientific doubt.

---

What Cancers Are Alleged in the Litigation?

Plaintiffs in MDL 2875 have alleged a range of cancer diagnoses they attribute to contaminated valsartan exposure. The cancers that appear most frequently in epidemiological literature examining nitrosamine exposure include:

• Liver cancer (hepatocellular carcinoma)
• Stomach cancer (gastric cancer)
• Colorectal cancer
• Bladder cancer

This list reflects what appears in published research and in legal filings — it is not a definitive medical determination. Establishing causation between NDMA exposure and a specific plaintiff’s cancer requires individual expert analysis considering exposure duration, dose, diagnosis timing, and other cancer risk factors.

The defense side of this litigation predictably argues that many of these cancers are common in the age group taking valsartan (hypertension patients tend to be older adults), that there are well-established independent risk factors for each cancer type, and that it is scientifically difficult to isolate NDMA exposure as the specific cause in any individual case. Plaintiffs’ experts counter with general causation evidence (NDMA causes these cancers in animal models), specific causation analysis (this plaintiff had meaningful exposure and no dominant competing risk factors), and epidemiological studies examining populations with elevated nitrosamine exposure.

No one should assume their cancer was caused by contaminated valsartan without medical and legal evaluation. Equally, no one who developed one of these cancers after taking recalled valsartan should dismiss the possibility without inquiry.

The tension between general and specific causation is where mass tort pharmaceutical litigation is won and lost. General causation — can this drug cause this type of cancer? — is typically established through expert testimony and is fought at the MDL level for all cases collectively. Specific causation — did this drug cause this plaintiff’s cancer? — is an individual question that each plaintiff must address with their own medical history and expert analysis.

---

Understanding MDL 2875: How Mass Tort Litigation Works

The formal name of the consolidated federal litigation is “In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation,” designated MDL 2875. It is pending in the U.S. District Court for the District of New Jersey.

Understanding what an MDL is — and isn’t — matters for plaintiffs considering their options.

MDL vs. Class Action: A Critical Distinction

Feature	MDL	Class Action
Individual cases	Each plaintiff retains a separate case	Plaintiffs are grouped into a single case
Discovery	Consolidated and shared for efficiency	Conducted collectively
Damages	Individualized — each plaintiff’s outcome may differ	Often uniform or formula-based
Settlement	Each plaintiff must approve their own resolution	Class representative negotiates for all
Opt-out	Plaintiffs join affirmatively	May need to opt out to preserve individual rights

In an MDL, the federal judiciary consolidates cases before a single judge to avoid duplicative discovery, inconsistent rulings on the same legal questions, and overwhelming multiple federal courts simultaneously. The transferee judge manages pretrial proceedings — including motions and discovery — while individual cases remain available for trial or individual resolution.

The 28 U.S.C. § 1407 transfer authority that enables MDLs was designed precisely for situations like pharmaceutical contamination: a single defect, many geographically dispersed victims, common factual and legal questions best resolved once rather than thousands of times. The transferee judge does not preside over individual trials — once pretrial proceedings conclude and a case is trial-ready, it is returned (“remanded”) to the originating district court for trial. In practice, however, most MDL cases resolve before reaching that stage, either through settlement or dismissal.

MDL 2875 expanded to include losartan and irbesartan after NDMA and NDEA contamination was found in those related ARB medications as well, broadening the potential plaintiff pool significantly.

Bellwether Trials

A key feature of large MDLs is the use of bellwether trials — representative cases selected and tried to test legal theories, evidence, and damages before the full docket. Outcomes in bellwether trials often inform settlement negotiations without resolving every individual case through trial.

For the latest status of MDL 2875 proceedings, the authoritative source is the official PACER system (Public Access to Court Electronic Records) or a qualified MDL attorney — litigation of this scale evolves continuously.

---

Who May Be Eligible to File a Valsartan Lawsuit?

Not every person who took valsartan has a viable legal claim, and not every cancer diagnosis following valsartan use is automatically connected to the contamination. General eligibility typically turns on several factors:

1. Use of Recalled Valsartan The starting question is whether the specific valsartan product you took was part of a recalled lot. If your medication was not manufactured by ZHP or another recalled source, your exposure profile differs fundamentally.

2. Duration of Use A longer period of use typically means more cumulative NDMA exposure. Many attorneys focus on plaintiffs who took contaminated valsartan for a meaningful period — often evaluated in terms of months or years, not days.

3. Cancer Diagnosis You generally need a documented cancer diagnosis. The cancer type matters: attorneys look for cancers that appear in the scientific literature examining nitrosamine exposure.

4. Timing and Causation The sequence matters. A cancer diagnosed after a significant period of contaminated valsartan use is more plausible as a candidate for litigation than a cancer that predated the use or was diagnosed immediately after use began (given typical cancer development timelines).

5. General Health History Other cancer risk factors in your history — family history, tobacco use, obesity, prior exposures — are not disqualifying, but they become part of the causation analysis. Defendants will argue alternative explanations.

None of these factors should be evaluated in isolation or without legal counsel. The purpose of consulting an attorney is precisely to have someone who understands the current state of the litigation assess your specific facts.

---

Categories of Damages in a Drug Liability Case

Drug liability cases in the U.S. generally recognize several categories of damages. Here is how they are typically framed, without any suggestion of specific amounts — which vary enormously based on individual circumstances, jurisdiction, and the specific facts of each case.

Damage Category	What It Covers
Medical expenses	Past treatment costs, ongoing care, future medical needs related to the cancer
Lost income	Wages lost due to illness, treatment recovery, disability
Loss of earning capacity	Future income impairment if the cancer affects long-term work ability
Pain and suffering	Physical pain and emotional distress associated with the cancer and treatment
Loss of consortium	Impact on spousal relationship (varies by jurisdiction)
Punitive damages	Available in some cases if defendant conduct is found to be egregious or reckless

Settlement amounts and verdicts in pharmaceutical litigation vary by injury severity, jurisdiction, individual case facts, and the stage at which a case resolves. Attorneys handling these cases on contingency typically do not collect fees unless there is a recovery — which is why consultation is generally available at no upfront cost to the plaintiff.

In mass tort MDLs, individual case value is often assessed through a structured matrix approach, where factors like cancer severity, treatment burden, age at diagnosis, and the strength of the causation case each affect where a given claim falls within a range. That matrix is negotiated between plaintiffs’ leadership counsel and defendants — it is not public until a settlement framework is announced.

Anyone claiming specific settlement amounts for MDL 2875 cases should be treated with skepticism. Case resolution in large MDLs is an ongoing, individualized process. Websites promising specific payout ranges are typically operating as lead-generation services, not as authoritative sources of case valuation data.

---

Statute of Limitations: Do Not Wait to Consult an Attorney

One of the most consequential practical points in any personal injury litigation is the statute of limitations — the legal deadline for filing a lawsuit. Missing it means losing the right to sue, regardless of how strong the underlying claim might be.

For drug injury cases:

• Statutes of limitations vary by state, typically ranging from two to four years
• The clock typically starts from either the date of injury or the date you discovered (or reasonably should have discovered) the connection between the drug and your injury — this is called the discovery rule
• Some states apply a separate accrual date for pharmaceutical injury claims when the contamination was not publicly known

For valsartan cases, a reasonable argument exists that the clock for many plaintiffs started running around the time the 2018 recall became public and news coverage made the NDMA-cancer connection widely known. Depending on your state and the specific facts, that window may already be closing or closed for some potential claimants.

State discovery rules add important nuance. In states with a strict “injury date” accrual rule, the limitations period may have begun at the cancer diagnosis — even if the plaintiff had no idea at that time that valsartan was involved. In states with a “discovery of cause” rule, the period may begin when the plaintiff reasonably discovered the connection to the contaminated drug. This distinction can make a difference of years in eligibility.

Some plaintiffs have had cases dismissed on limitations grounds while others in different states with the same factual profile remained eligible. This is not a generic legal question with a uniform answer — it is a state-specific analysis that requires knowledge of the exact jurisdiction and facts.

This is not a situation where waiting is advisable. Even if you are uncertain whether your case has merit, a consultation with a qualified mass tort attorney is the only way to understand your deadline with confidence.

---

How to Check Whether Your Prescription Was Recalled

If you are unsure whether the valsartan you took was part of the recall, here is a practical approach:

Step 1: Gather your prescription records. Contact your pharmacy or physician’s office for records of which valsartan product you received, including the manufacturer/distributor and dates of use. Many pharmacies retain dispensing records for seven or more years.

Step 2: Find the lot number if possible. Recall notices are specific to manufacturing lot numbers. If you still have original pill bottles, the lot number is typically printed on the label.

Step 3: Search the FDA recall database. Visit fda.gov and search for valsartan recalls. The FDA published detailed recall notices listing specific manufacturers, NDC codes, and lot numbers for affected products.

Step 4: Contact your pharmacy directly. Pharmacies received direct notification of recalls and can often confirm whether a specific dispensed lot was affected.

Step 5: If you cannot determine definitively, consult an attorney. Mass tort attorneys experienced in MDL 2875 have developed processes for verifying prescription history and recalled lots. Many work with pharmaceutical record retrieval services as part of case intake.

---

What to Do If You Believe You Have a Claim

Document Everything Now

The most important immediate action is gathering and preserving documentation. Memories fade; physical records provide the evidentiary foundation for a case.

Priority documents to gather:

• Prescription records for all valsartan (and related ARB) medications
• Pharmacy dispensing records showing manufacturer and lot numbers
• Cancer diagnosis records (biopsy reports, oncology records, hospital records)
• Medical bills and insurance records related to cancer treatment
• Any communications from your pharmacy or physician about the recall
• Social Security or disability records if applicable

Do not wait for a clear answer on whether your case is viable before starting this documentation process. Records can be harder to obtain as time passes — pharmacies may purge old records, providers close practices, and paperwork gets lost.

Real-World Scenario: A Patient Discovers the Recall Late

Consider a patient who was prescribed generic valsartan in 2016 for hypertension. He took it daily until 2020, when his physician switched him to a different medication class for unrelated reasons. In 2022, he was diagnosed with bladder cancer.

In 2023, he learned from a news article that valsartan had been recalled for NDMA contamination. By that point, he has a narrow window — or possibly a missed window, depending on his state’s discovery rule and when he “should have known” about the connection.

The lesson: earlier awareness matters. If you took valsartan at any point before or during the 2018 recall period and later developed cancer, this is a conversation worth having with an attorney promptly.

Real-World Scenario: A Family Member’s Post-Diagnosis Discovery

A woman whose husband died of gastric cancer in 2019 discovers in 2024 that he had been taking ZHP-sourced valsartan for six years prior to his diagnosis. She asks whether she can still pursue a wrongful death claim.

The answer depends heavily on the state’s wrongful death statute of limitations, discovery rules, and whether the estate was previously closed. Some states allow extended time for wrongful death claims when the connection between conduct and death was not reasonably discoverable earlier. This is exactly the type of nuanced factual analysis that requires legal counsel — not a generic answer.

Real-World Scenario: Someone Who Took Valsartan But Has No Cancer Diagnosis

A person took contaminated valsartan for three years. She has no cancer diagnosis. She wants to know if she has any legal recourse.

Generally, pharmaceutical personal injury claims require an actual injury — a cancer diagnosis, not just risk of cancer. Medical monitoring claims (seeking court-ordered screening for plaintiffs at elevated cancer risk) have been pursued in some pharmaceutical contamination cases, though the availability and success of such claims varies significantly by jurisdiction.

Without a current diagnosis, the more practical focus is proactive: inform your oncologist or primary care physician about your contaminated valsartan history, document it in your medical record, and stay current on cancer screenings appropriate to your risk profile.

---

Finding Legal Representation for an MDL Case

Mass tort MDL litigation is handled almost exclusively on a contingency fee basis. This means:

• You pay no upfront legal fees
• The attorney receives a percentage of any recovery
• If there is no recovery, you owe no attorney’s fee (though some costs may still apply — review the specific fee agreement)

For MDL 2875, most plaintiffs are represented by attorneys who specialize in pharmaceutical litigation and mass torts. The Plaintiffs’ Steering Committee (PSC) in the MDL coordinates litigation strategy, discovery, and negotiations on behalf of the plaintiff class — but individual plaintiffs still need their own retained counsel.

When evaluating an attorney or law firm:

• Confirm they have experience in pharmaceutical MDL litigation specifically
• Ask about their role in MDL 2875 or similar pharmaceutical cases
• Understand the contingency fee percentage and cost recovery terms before signing
• Be cautious of high-pressure or overly guaranteed outcomes — no attorney can promise results in litigation
• Ask who will actually handle your case day-to-day — a named partner and the associate assigned to your file are often different people

Contingency fees in mass tort cases typically range from 33% to 40% of any recovery, though this varies by firm and jurisdiction. Some firms also deduct case costs (expert fees, medical record retrieval costs) from the recovery. Understand what you are agreeing to before signing a retainer.

Avoid operations that function primarily as lead-generation services and then refer your case to a distant firm without direct attorney involvement in your matter. In large MDLs, a secondary market for case referrals develops; the firm that took your call may have no actual role in your litigation. Ask directly: will this firm represent me in the MDL, or will my case be referred elsewhere?

The best valsartan litigation attorneys are typically those with a track record in other pharmaceutical MDLs (opioids, Roundup, talcum powder, pelvic mesh) and who can articulate specifically what role they are playing in MDL 2875 discovery or motion practice.

---

The Broader Nitrosamine Problem: Why This Case Matters Beyond Valsartan

The valsartan contamination was not an isolated incident. The FDA’s investigation triggered industry-wide testing that found NDMA and related nitrosamine impurities in other medications — including ranitidine (Zantac), metformin (a common diabetes medication), and other ARBs including losartan and irbesartan (both included in MDL 2875).

Ranitidine’s situation was even more fundamental: the FDA determined that NDMA forms from the ranitidine molecule itself under storage conditions, not only from manufacturing contamination, which led to a market withdrawal of all ranitidine products in 2020.

This pattern reveals a systemic problem in pharmaceutical supply chains that relied heavily on overseas API manufacturers with manufacturing processes that were not systematically tested for nitrosamine formation. The regulatory response has included new FDA guidance requiring nitrosamine risk assessments across drug categories — a significant shift in how pharmaceutical manufacturing is evaluated.

For affected patients, the valsartan case is part of a larger story about what happens when cost optimization in global pharmaceutical supply chains intersects with inadequate testing protocols and chronic regulatory detection gaps.

---

Checklist: Steps for Potential Valsartan Claimants

Use this as a practical framework, not a substitute for legal advice:

• Determine whether you took valsartan, and for what period (2012–2020 is the relevant window for most ZHP-sourced API)
• Contact your pharmacy to obtain prescription records and manufacturer information
• Check the FDA recall database for your specific product and lot number
• Document any cancer diagnosis (type, date, treating oncologist, biopsy records)
• Gather medical records related to cancer treatment
• Research your state’s statute of limitations for pharmaceutical injury claims
• Consult a qualified mass tort attorney — most offer free initial consultations
• Do not sign anything with a law firm or settlement service without understanding the terms
• Notify your current physicians of your contaminated valsartan history for your medical record

---

Related Posts

• Stock Capital Gains Tax Guide: How to Minimize What You Owe in 2026
• SCHD Dividend ETF Deep Dive: Is It Still the Best Income ETF in 2026?
• AAPL Stock Outlook 2026: What Analysts Are Missing About Apple’s AI Transition
• AI Stocks Investment Guide 2026: Which Picks Have Durable Earnings Power?

---

This article is for informational purposes only and does not constitute legal advice. The legal landscape surrounding MDL 2875 and valsartan litigation is complex and evolving. Please consult a qualified attorney for guidance specific to your situation, including the application of statutes of limitations in your state.